Skip to main content
    C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    +0.12 (+16.75%)

    Market Cap: $56.49M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cardiff Oncology Inc (CRDF) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Cardiff Oncology (CRDF) to earn -$0.56 per share in the fiscal year ending Dec 31, 2026, on revenue of $364500. Of 6 analysts, 3 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.33, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 50% of the ratings.

    RatingAnalystsShare
    Strong Buy116.7%
    Buy233.3%
    Hold350.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 5.6%.

    Fiscal year ending Dec 31, 2026
    -$0.56
    EPS consensus, revenue $364500
    Fiscal year ending Dec 31, 2027
    -$0.52
    EPS consensus, revenue $385000
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.56-$0.56 to -$0.553$364500$166000 to $4450006
    Dec 31, 2027-$0.52-$0.76 to -$0.334$385000N/A5

    Quarterly Estimates

    The EPS consensus rises from -$0.16 for the quarter ending Dec 31, 2026 to -$0.13 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.16-$0.21 to -$0.099$84997N/A9
    Mar 31, 2027-$0.13-$0.16 to -$0.092$116670$50000 to $2000003

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 10 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202640
    Fiscal year ending Dec 31, 202740
    Quarter ending Mar 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.55.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.56-$0.56-$0.56-$0.56-$0.55N/A
    Fiscal year ending Dec 31, 2027-$0.52-$0.54-$0.54-$0.60-$0.63N/A
    Quarter ending Mar 31, 2027-$0.13-$0.13-$0.13-$0.15-$0.15N/A

    Frequently Asked Questions About CRDF

    What is the CRDF stock forecast?

    Consensus analyst estimates put Cardiff Oncology's EPS at -$0.56 for the fiscal year ending Dec 31, 2026, on revenue of $364500. The consensus rating from 6 analysts is Buy.

    How do analysts rate CRDF stock?

    Of 6 analysts covering Cardiff Oncology, 1 rates it Strong Buy, 2 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CRDF next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.56, with estimates from -$0.56 to -$0.55 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.52, with estimates from -$0.76 to -$0.33 from 4 analysts.

    What revenue do analysts expect from Cardiff Oncology next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $364500, with estimates from $166000 to $445000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $385000.

    How many analysts cover CRDF?

    6 analysts rate Cardiff Oncology stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.